Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis

Loading news article.

Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis | WAPE

Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis

Article summary

Related companies

Comments —